Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  Aleafia Health Inc    ALEF   CA01444Q1046


News SummaryMost relevantAll newsOfficial PublicationsSector news

Aleafia Health Secures Health Canada Permits to Export Cannabis Products to Australia

share with twitter share with LinkedIn share with facebook
share via e-mail
07/02/2019 | 07:01am EDT

Permits Allow Company to Begin its First International Cannabis Product Shipment 
Products to be Distributed by Australian-based Strategic Partner CannaPacific

TORONTO, July 02, 2019 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF, FRA: ARAH) (“Aleafia Health” or the “Company”) has received multiple Export Permits (the “Permits”) from Health Canada, which allow the Company to begin its first international cannabis product shipment. The Company expects to ship its branded medical cannabis oils in the next month, which will be distributed by Australian Licensed Producer CannaPacific Pty. Limited (“CannaPacific”). Aleafia Health owns a 10 per cent equity stake in CannaPacific.

“The receipt of Health Canada Export Permits enables Aleafia Health to sell high-margin, value-added cannabis products across international borders for the first time, representing a major milestone as we augment our global distribution platform,” said Aleafia Health Chairman Julian Fantino. “We continue to prove the international viability of our highly differentiated cannabis health and wellness ecosystem with products, clinic operations, education and distribution. With among the largest cultivation and extraction footprints in Canada coming online, we will continue to look to new international markets.”

The Permits allow specifically for the export of the Company’s branded medical cannabis oils, including drops and sprays. As previously announced, the Company has already received the corresponding Permits to Import medical cannabis products from the Australian Government’s Department of Health.

“This is such a tremendous milestone for CannaPacific. Our relationship with Aleafia Health continues to accelerate our strategic vision of leadership in the Australasian medical cannabis market,” said CannaPacific CEO Joshua Dennis. “We have the facility, the proven management team, and now the product portfolio to continue executing towards our goal.”

For Investor and Media Relations, please contact:

Nicholas Bergamini, VP Investor Relations
LEARN MORE: www.AleafiaHealth.com

About Aleafia Health:

Aleafia Health is a leading, vertically integrated cannabis health and wellness company with four primary business units: Cannabis Cultivation & Products, Health & Wellness Clinics, Cannabis Education, and Consumer Experience with ecommerce, retail distribution and provincial supply agreements.

Aleafia Health owns three major cannabis product & cultivation facilities, two of which are licensed and operational including the first large-scale, operational outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules and sprays. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and has international operations in three continents.

Innovation is at the heart of Aleafia Health competitive advantage. The Company maintains a medical cannabis dataset with over 10 million data points to inform proprietary illness-specific product development and its highly differentiated education platform FoliEdge Academy. The Company is committed to creating sustainable shareholder value and has been named the 2019 top performing company of the year by the TSX Venture Exchange prior to graduation to the TSX.

About CannaPacific:

CannaPacific is a licensed Medical Cannabis Company based in Newcastle and the Macleay Valley on the mid-north coast of New South Wales (NSW), Australia. CannaPacific has been granted licenses to cultivate and research medical cannabis in Australia and is in the process of constructing a 108,000 sq. ft. greenhouse cultivation and research facility.  This project will position CannaPacific as a high-quality low-cost Australian producer.  The CannaPacific Team comprises experts in the medical, clinical trials, plant Science, technology and pharmaceutical industries with vast experience and world class capability.

LEARN MORE: www.cannapacific.com.au 

Forward Looking Information

This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aleafia Health or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation. 

Primary Logo

© GlobeNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
08/14Aleafia Health Reports Record Revenue in Q2 2019, 159% Q/Q Revenue Increase
08/07Aleafia Health to Announce 2019 Second Quarter Financial Results
08/01Aleafia Health Completes Largest Cannabis Order to Date, Provides Facility Up..
07/15Aleafia Health Secures Health Canada Licence Amendment for Entire 1.1M sq. ft..
07/12YIELD GROWTH Announces Definitive Agreement for Exclusive Distribution of Urb..
07/11Aleafia Health Added to NYSE-Listed The Cannabis ETF
07/02Aleafia Health Secures Health Canada Permits to Export Cannabis Products to A..
06/27ALEAFIA HEALTH : IIROC Trade Resumption - ALEF.DB
06/27ALEAFIA HEALTH : IIROC Trade Resumption - ALEF.WT
06/27Aleafia Health Announces Closing of $40.25 Million Public Offering, Including..
More news
Financials (CAD)
Sales 2019 16,2 M
EBIT 2019 -30,6 M
Net income 2019 -54,5 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020 -
Capi. / Sales2019 19,4x
Capi. / Sales2020 1,93x
Capitalization 313 M
Duration : Period :
Aleafia Health Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALEAFIA HEALTH INC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 2
Average target price 3,00  CAD
Last Close Price 1,14  CAD
Spread / Highest target 163%
Spread / Average Target 163%
Spread / Lowest Target 163%
EPS Revisions
Geoffrey M. Benic Chief Executive Officer
Julian Fantino Executive Chairman
Benjamin Ferdinand Chief Financial Officer
Gary Goodyear Director & President-Clinic Operations
Michael Verbora Director & Chief Medical Officer